Product Description
the lower price 98% white powder Canagliflozin;JNJ 24831754ZAE;JNJ 28431754;JNJ 28431754AAA;TA 7284 842133-18-0
AI Product Description
*The following content is generated by AI and is for reference only.
Canagliflozin, chemically designated as JNJ-24831754 or JNJ 28431754, is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Marketed under various internal research codes such as TA 7284 and specific batch identifiers like ZAE or AAA, this compound is widely recognized in pharmaceutical research for its therapeutic potential in managing type 2 diabetes. As a white crystalline powder with high purity levels often exceeding 98%, it represents a significant advancement in glucose-lowering therapies.
The molecular formula of Canagliflozin is C26H25NO8S, corresponding to a molecular weight of approximately 487.54 g/mol. Its CAS registry number is 856507-05-0, which serves as the unique identifier for regulatory and scientific documentation globally. The drug functions by blocking SGLT2 receptors located in the proximal convoluted tubule of the kidney. Under normal physiological conditions, these receptors are responsible for reabsorbing the majority of filtered glucose back into the bloodstream. By inhibiting this process, Canagliflozin promotes urinary glucose excretion, thereby lowering blood glucose levels independent of insulin secretion. This mechanism offers a distinct advantage over traditional antidiabetic agents, reducing the risk of hypoglycemia while potentially aiding in weight loss and lowering blood pressure.
In clinical settings, Canagliflozin has demonstrated efficacy in improving glycemic control when used as monotherapy or in combination with other antidiabetic medications. Beyond glycemic management, recent studies suggest cardiorenal protective benefits, making it valuable for patients with established cardiovascular disease or chronic kidney disease. The availability of high-purity Canagliflozin powder facilitates extensive preclinical research, allowing scientists to explore novel delivery systems and combination therapies. While primarily developed for diabetes treatment, ongoing investigations continue to uncover its broader metabolic implications. Researchers must ensure strict adherence to safety protocols when handling the raw material, given its biological activity. Ultimately, Canagliflozin stands as a cornerstone in modern endocrinology, offering a targeted approach to metabolic regulation that addresses both immediate glucose control and long-term organ protection.